Pyxis Oncology (PYXS) EPS (Basic) Growth (1y) (2021 - 2026)
Pyxis Oncology (PYXS) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | -16.29% |
| 10 | Pyxis Oncology | 198.05 Mn | 165.06 Mn | - | -33.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.60% |
| Dec 31, 2025 | 51.38% |
| Sep 30, 2025 | -0.72% |
| Jun 30, 2025 | -3.65% |
| Mar 31, 2025 | -61.53% |
| Dec 31, 2024 | -20.90% |
| Sep 30, 2024 | 39.83% |
| Jun 30, 2024 | 38.67% |
| Mar 31, 2024 | 68.45% |
| Dec 31, 2023 | 53.11% |
| Sep 30, 2023 | 53.67% |
| Jun 30, 2023 | 61.24% |
| Mar 31, 2023 | 26.37% |
| Dec 31, 2022 | 78.38% |
| Sep 30, 2022 | 95.73% |
| Jun 30, 2022 | 70.17% |
| Mar 31, 2022 | 96.28% |
| Dec 31, 2021 | -3.85% |
| Sep 30, 2021 | -899.84% |